Overview

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

Status:
Terminated

Trial end date:
2007-05-01

Target enrollment:

Participant gender:

Summary

The purpose of the trial is to determine the safety and efficacy of Gleevec" in idiopathic hypereosinophilic syndrome (HES) and to characterize the molecular basis for the therapeutic benefit of Gleevec" in HES.

Phase:

Phase 2

Details

Lead Sponsor:

Stanford University
Steven E. Coutre

Collaborator:

Novartis

Treatments:

Imatinib Mesylate